165 related articles for article (PubMed ID: 22024351)
21. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF.
Fernández Lorente A; Acosta Brooks S; Neninger Vinageras E; Barroso Alvarez Mdel C; Wilkinson Brito B; Troche Concepción M; Martínez Pérez LB; Viada González CE; Crespo Diaz T; Casacó Parada AR
World J Surg Oncol; 2013 Oct; 11():275. PubMed ID: 24127898
[TBL] [Abstract][Full Text] [Related]
22. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
Zhang JY; Zhu L; Yang HK; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802
[TBL] [Abstract][Full Text] [Related]
23. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment.
Gonzalez G; Crombet T; Lage A
Curr Cancer Drug Targets; 2011 Jan; 11(1):103-10. PubMed ID: 21062240
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
Xing P; Wang H; Yang S; Han X; Sun Y; Shi Y
BMC Immunol; 2018 Apr; 19(1):14. PubMed ID: 29661145
[TBL] [Abstract][Full Text] [Related]
25. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
Suárez GM; Catalá M; Peña Y; Portela S; Añé-Kourí AL; González A; Lorenzo-Luaces P; Díaz M; Molina MLA; Pereira K; Hernández JC; Ramos R; Reyes MC; Ledón N; Mazorra Z; Crombet T; Lage A; Saavedra D
Front Oncol; 2022; 12():823287. PubMed ID: 35155258
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic vaccines in non-small cell lung cancer.
Socola F; Scherfenberg N; Raez LE
Immunotargets Ther; 2013; 2():115-24. PubMed ID: 27471692
[TBL] [Abstract][Full Text] [Related]
27. Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Giménez-Capitán A; Viteri S; Cardona AF; D'Hondt E; Karachaliou N; Rosell R
J Thorac Oncol; 2018 Sep; 13(9):1324-1337. PubMed ID: 29751136
[TBL] [Abstract][Full Text] [Related]
28. Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.
Rosell R; Neninger E; Nicolson M; Huber RM; Thongprasert S; Parikh PM; D'Hondt E
J Thorac Oncol; 2016 Nov; 11(11):1954-1961. PubMed ID: 27566188
[TBL] [Abstract][Full Text] [Related]
29. CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.
Cheng JY; Kananathan R
Hum Vaccin Immunother; 2012 Dec; 8(12):1799-801. PubMed ID: 22906936
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.
Gonzalez G; Crombet T; Torres F; Catala M; Alfonso L; Osorio M; Neninger E; Garcia B; Mulet A; Perez R; Lage R
Ann Oncol; 2003 Mar; 14(3):461-6. PubMed ID: 12598354
[TBL] [Abstract][Full Text] [Related]
31. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
32. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
[TBL] [Abstract][Full Text] [Related]
33. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
34. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease.
Rodriguez G; Gonzalez G; Crombet T; Lage A
Expert Rev Respir Med; 2011 Jun; 5(3):337-42. PubMed ID: 21702656
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
37. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Janmaat ML; Giaccone G
Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
[TBL] [Abstract][Full Text] [Related]
38. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]